Literature DB >> 8984914

Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation.

F Bell1, A Martin, C Blondeau, C Thornton, J Chaplais, A Finn.   

Abstract

A total of 146 infants were immunised at ages 2, 3, and 4 months with a combined diphtheria, tetanus, pertussis (DTP)--Haemophilus influenzae type b (Hib) tetanus toxoid conjugate (PRP-T) vaccine (Pasteur Merieux) to assess the antibody response and adverse events associated with immunisation. Adverse events, including fever, were recorded by parents in a diary for three days following each injection. Blood was taken before the first immunisation and four weeks after the third immunisation to assess antibody response. Data were compared with those from historical controls who had received DTP and PRP-T vaccines by separate injection. The combined vaccine was well tolerated. Rates of local and general reactions were similar to those reported for infants immunised by separate injection. All infants achieved protective antibody titres (> 0.01 IU/ml) for diphtheria and tetanus; 98% acquired Hib (PRP) antibody > 0.15 microgram/ml and 82.5% > 1.0 microgram/ml. Pertussis antibody titres (pertussis toxin, filamentous haemagglutinin, total agglutinins, and agglutinins 2 and 3) showed appreciable rise following immunisation. DTP and PRP-T vaccines provide similar antibody responses and adverse effects whether mixed in the same syringe or administered by separate injection. The vaccines could be combined for use in the United Kingdom primary immunisation schedule.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984914      PMCID: PMC1511738          DOI: 10.1136/adc.75.4.298

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  28 in total

1.  Differences in antibody response to whole-cell pertussis vaccines.

Authors:  K M Edwards; M D Decker; N A Halsey; B A Koblin; T Townsend; B Auerbach; D T Karzon
Journal:  Pediatrics       Date:  1991-11       Impact factor: 7.124

2.  Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule.

Authors:  R Booy; S A Taylor; S R Dobson; D Isaacs; G Sleight; S Aitken; H Griffiths; H Chapel; R T Mayon-White; J A Macfarlane
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

3.  Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain.

Authors:  L J Baraff; C R Manclark; J D Cherry; P Christenson; S M Marcy
Journal:  Pediatr Infect Dis J       Date:  1989-08       Impact factor: 2.129

4.  Trial of a new acellular pertussis vaccine in healthy adult volunteers.

Authors:  D A Rutter; L A Ashworth; A Day; S Funnell; F Lovell; A Robinson
Journal:  Vaccine       Date:  1988-02       Impact factor: 3.641

5.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

6.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  H Käyhty; H Peltola; V Karanko; P H Mäkelä
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

7.  The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age.

Authors:  C Ferreccio; J Clemens; A Avendano; I Horwitz; C Flores; L Avila; M Cayazzo; B Fritzell; M Cadoz; M Levine
Journal:  Pediatr Infect Dis J       Date:  1991-10       Impact factor: 2.129

8.  Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants.

Authors:  N Watemberg; R Dagan; Y Arbelli; I Belmaker; A Morag; L Hessel; B Fritzell; A Bajard; L Peyron
Journal:  Pediatr Infect Dis J       Date:  1991-10       Impact factor: 2.129

9.  Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.

Authors:  R Booy; S J Aitken; S Taylor; G Tudor-Williams; J A Macfarlane; E R Moxon; L A Ashworth; R T Mayon-White; H Griffiths; H M Chapel
Journal:  Lancet       Date:  1992-02-29       Impact factor: 79.321

10.  Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine.

Authors:  J D Clemens; C Ferreccio; M M Levine; I Horwitz; M R Rao; K M Edwards; B Fritzell
Journal:  JAMA       Date:  1992-02-05       Impact factor: 56.272

View more
  4 in total

1.  A search for the evidence supporting community paediatric practice.

Authors:  M C Rudolf; N Lyth; A Bundle; G Rowland; A Kelly; S Bosson; M Garner; P Guest; M Khan; R Thazin; T Bennett; D Damman; V Cove; V Kaur
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

Review 2.  Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease.

Authors:  M J Robinson; F Campbell; P Powell; D Sims; C Thornton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

Review 4.  Bacterial meningitis: the impact of vaccination.

Authors:  Nick Makwana; F Andrew I Riordan
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.